论文部分内容阅读
目的观察MACOPB方案治疗复发或难治性非霍奇金淋巴瘤(NHL)的近期疗效及不良反应。方法对28例难治复发性NHL患者应用MACOPB方案(MTX 400 mg/m2第2、6、10周静滴,24 h后四氢叶酸钙15 mg/m2,qh×6次解救,MIT 6 mg/m2第1、3、5、7、9、11周静滴,CTX 400 mg/m2第1、3、5、7、9、11周静滴,VCR 2 mg第2、4、6、8、10、12周静滴,DXM 10 mg qd×2周静滴后减量,BLM 10mg/m2第4、8、12周静滴)化疗,评定疗效。结果 28例患者总有效率为78.6%(22/28),完全缓解(CR)率为60.7%(17/28),部分缓解(PR)率为17.9%(5/28)。毒副反应主要为骨髓抑制、黏膜炎、胃肠道反应等。全组病例支持治疗下均能完成所有化疗,全组无致死性毒性反应发生。结论 MACOPB方案可用于治疗难治复发性NHL,有较好的近期疗效,治疗相关不良反应轻微,易于控制。为能够再次缓解的复发淋巴瘤患者进行造血干细胞移植提供了治疗机会。
Objective To observe the short-term curative effect and adverse reactions of MACOPB regimen in relapsed or refractory non-Hodgkin’s lymphoma (NHL). Methods MACOPB was given to 28 patients with refractory recurrent NHL. MTX 400 mg / m2 was intravenously administered at the 2nd, 6th, and 10th weeks. After 24 h, calcium tetrahydrofolate 15 mg / m2, qh × 6 times, MIT 6 mg / m2 1,3,5,7,9,11 weeks intravenous infusion, CTX 400 mg / m2 1,3,5,7,9,11 weeks intravenous infusion, VCR 2 mg 2,4,6,8 , 10,12 weeks of intravenous infusion, DXM 10 mg qd × 2 weeks intravenous drip reduction, BLM 10mg / m2 4,8,12 weeks intravenous) chemotherapy to assess the efficacy. Results The total effective rate was 78.6% (22/28) in 28 cases, 60.7% (17/28) in complete remission (CR) and 17.9% (5/28) in partial remission. Toxicity mainly for bone marrow suppression, mucositis, gastrointestinal reactions. All patients under the support of treatment can complete all chemotherapy, the whole group of non-fatal toxicity occurred. Conclusions The MACOPB regimen can be used to treat refractory recurrent NHL with good short-term curative effect. The treatment-related adverse reactions are mild and easy to control. Provides a therapeutic opportunity for hematopoietic stem cell transplantation for relapsed lymphoma patients.